Theratechnologies (THERF) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Theratechnologies (OTCMKTS:THERF) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.

Separately, Royal Bank of Canada began coverage on shares of Theratechnologies in a research note on Tuesday, September 4th. They issued a sector perform rating for the company.

THERF opened at $6.55 on Thursday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.52 and a current ratio of 2.89. Theratechnologies has a 1 year low of $3.90 and a 1 year high of $11.25.

Theratechnologies (OTCMKTS:THERF) last posted its earnings results on Thursday, October 4th. The company reported $0.02 earnings per share (EPS) for the quarter. Theratechnologies had a negative net margin of 17.11% and a negative return on equity of 17.75%. The firm had revenue of $13.53 million during the quarter.

Theratechnologies Company Profile

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

Recommended Story: Buyback

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply